Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 546-547
DOI: 10.1111/apt.70817 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 20.06.2026. Verfasst von Nicolas Richard und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Gastroenterology, Univ Rouen Normandie, INSERM, ADEN UMR1073, "Nutrition, Inflammation and Microbiota-Gut-Brain Axis", CHU Rouen, Rouen, France.
- Department of Gastroenterology, Amiens University Hospital and PeriTox, Université de Picardie, Amiens, France.
Zitieren
APA
Richard, N., & Fumery, M. (2026). Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. Alimentary Pharmacology & Therapeutics, 64(4), 546-547. https://doi.org/10.1111/apt.70817
Vancouver
Richard N, Fumery M. Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply. Alimentary Pharmacology & Therapeutics. 2026;64(4):546-547. doi:10.1111/apt.70817
BibTeX
@article{Richard2026,
author = {Richard, Nicolas and Fumery, Mathurin},
title = {Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {4},
pages = {546--547},
doi = {10.1111/apt.70817}
}
EUVIMED